**Core tip:** The increasing antimicrobial resistance of *Helicobacter pylori* (*H. pylori*) is an urgent, global issue. Although current *H. pylori* treatment regimens provide acceptable eradication rates, these regimens could also be improved to optimize antibiotic usage and prevent antimicrobial resistance because these regimens use multiple antibiotic agents and have a long treatment duration. Dual therapy consisting of vonoprazan and amoxicillin may be an alternative treatment regimen for *H. pylori* eradication in an era of growing antimicrobial resistance and may provide sufficient *H. pylori* eradication rates and may help prevent future antimicrobial resistance of *H. pylori*.

INTRODUCTION
============

*Helicobacter pylori* (*H. pylori*) infection, one of the most common bacterial infections, affects approximately 50% of the world's population\[[@B1]\]. *H. pylori* infection is a major cause of gastritis, gastric and duodenal ulcers, mucosal associated lymphoid tissue, and gastric cancer\[[@B2]\]. *H. pylori* eradication treatment has been proven to improve gastric inflammation, promote ulcer healing, and reduce the incidence of gastric cancer\[[@B3],[@B4]\]. Furthermore, a "test-and-treat" approach is advocated for detecting and eradicating *H. pylori* in patients with dyspeptic symptoms but low gastric cancer risk\[[@B5]\].

*H. pylori* eradication treatment is becoming more challenging due to increasing antimicrobial resistance. Previously, a 7-d standard triple therapy consisting of a proton pump inhibitor (PPI), amoxicillin (AMPC), and clarithromycin (CAM) was recommended for eradicating *H. pylori*\[[@B6]\]. However, there has been a significant reduction in the eradication rate achieved with this regimen due to the increase in antimicrobial resistance of *H. pylori*. Resistance of *H. pylori* has reached alarming levels worldwide, which greatly affects the efficacy of treatment. The World Health Organization (WHO) recently published its first ever list of antimicrobial resistant "priority pathogens," which is a catalogue of 12 families of bacteria posing the greatest threat to human health. They indicated three priority statuses-critical, high, and medium-with CAM-resistant *H. pylori* being categorized as a high priority bacterium in the same tier as vancomycin-resistant *Enterococcus faecium* and methicillin-resistant *Staphylococcus aureus*. Furthermore, resistance to metronidazole (MNZ) and fluoroquinolones, which are mainly used as rescue therapies\[[@B7]\], has also increased more recently to over 15% in many regions of the world\[[@B8],[@B9]\]. Thus, the mere avoidance of CAM in *H. pylori* eradication treatment is not enough to prevent and decrease antimicrobial resistance of *H. pylori*. Actually, a recent study of the influence of a government-introduced, restrictive antibiotic policy on the rates of resistance of *H. pylori* in Taiwan indicated an increase in levofloxacin resistance since the restriction of macrolides\[[@B10]\].

RECENT STANDARD *H. PYLORI* THERAPIES AND THE CONCERN FOR ANTIMICROBIAL RESISTANCE
==================================================================================

Treatment regimens are expected to overcome the increasing prevalence of resistant strains of H. pylori and achieve a \> 90% eradication rate. The eradication rates for first-line *H. pylori* treatment regimens published in meta-analysis and in a study of eradication rates of vonoprazan-based dual therapy are shown in Table [1](#T1){ref-type="table"}. Recently, bismuth-containing quadruple therapy (BQT) or non-bismuth concomitant quadruple therapy (CQT) has been recommended by international guidelines as a first-line treatment for *H. pylori* in areas of high CAM and/or MNZ resistance\[[@B5],[@B11],[@B12]\]. Both BQT and CQT contain PPI and two to three kinds of antibiotic agents including AMPC, CAM, MNZ, nitroimidazole, and tetracycline with longer treatment durations of 10-14 d. It is reported that acceptable eradication rates of \> 90% have been obtained by both regimens. Although BQT and CQT provide acceptable *H. pylori* eradication rates, they have many limitations, such as a complicated protocol, high cost, adverse side effects, and poor patient compliance due to multiple drug combinations\[[@B13]\]. Furthermore, these regimens must not contribute to antimicrobial resistance of *H. pylori*; moreover, they may promote future resistance because of the use of multiple antibiotics for a long duration. The alarming global rates of *H. pylori* resistance in treatment-naïve patients can be correlated with the increasing and uncontrolled use of antibiotics that are commonly used in *H. pylori* empirical therapy and in therapy for other common infections in the general population\[[@B14]\]. Increased antibiotic usage worldwide has led to antimicrobial resistance among many bacteria, including *H. pylori*, resulting in falling success rates of *H. pylori* eradication treatment. These regimens could also be improved to optimize antibiotic usage to prevent antimicrobial resistance.

###### 

Treatment regimens for first-line *Helicobacter pylori* therapies and its successful eradication rates

  **Regimens**                      **PPI**                                                                                                                                  **Antibiotics**                                                            **Treatment duration**          **Eradication rates**
  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------- ------------------------------
  Bismuth quadruple therapy         Esomeprazole 20-40 mg *bid*; Omeprazole 20-40 mg *bid*                                                                                   TC 125 mg *qid*; MNZ 125 mg *qid*                                          10 d                            90%\[[@B35]\]
  Concomitant quadruple therapy     Esomeprazole 20-40 mg *bid*; Lansoprazole 30 mg *bid*; Omeprazole 20-40 mg *bid*; Pantoprazole 40 mg *bid*; Rabeprazole 10-20 mg *bid*   AMPC 750 mg-1 g *bid*; CAM 200-500 mg *bid*; MNZ or TNZ 250-500 mg *bid*   5-14 d                          83%\[[@B36]\]
  Standard triple therapy           Esomeprazole 40 mg *bid*; Lansoprazole 30 mg *bid*; Pantoprazole 40 mg *bid*; Rabeprazole 10-20 mg *bid*                                 AMPC 500 mg-1 g *bid*; CAM 200-500 mg *bid*                                7 d\[[@B37]\]; 14 d\[[@B38]\]   73%\[[@B37]\]; 81%\[[@B38]\]
  High dose dual therapy            Esomeprazole 20 mg *qid*; Omeprazole 40 mg *qid*; Rabeprazole 10-20 mg *qid*                                                             AMPC 750 mg *qid*                                                          14 d                            86%\[[@B39]\]
  Vonoprazan based triple therapy   vonoprazan 20 mg *bid*                                                                                                                   AMPC 750 mg *bid*; CAM 200-400 mg *bid*                                    7 d                             88%\[[@B37]\]
  Vonoprazan based dual therapy     vonoprazan 20 mg *bid*                                                                                                                   AMPC 500 mg tid                                                            7 d                             94%\[[@B32]\]

PPI: Proton pump inhibitor; TC: Tetracycline; MNZ: Metronidazole; AMPC: Amoxicillin; CAM: Clarithromycin; TNZ: Tinidazole.

WHO launched the Global Action Plan on Antimicrobial Resistance to ensure, for as long as possible, the continuity of the ability to treat and prevent infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them. Five objectives are listed in this document and the fourth objective is "to optimize the use of antimicrobial medicines in human and animal health." They state that "extent of reduction in global human consumption of antibiotics, the consumption of antibiotics used in food production, and the use of medical and veterinary antimicrobial agents for applications other than human and animal health" are a potential measure of effectiveness for optimizing the use of antimicrobial medicines in human and animal health. Thus, the increase in resistance to CAM and the existence of multi-resistance to various families of antibiotics must be addressed by the appropriate use of antibiotics in *H. pylori* treatment. Antimicrobial susceptibility testing is the best way to optimize and reduce antibiotics for *H. pylori* eradication treatment as well as treating other common infections. Antimicrobial susceptibility testing is recommended to enable tailoring of the eradication therapy presented in the international guidelines\[[@B5]\], to ensure successful eradication\[[@B15],[@B16]\]. However, antimicrobial susceptibility testing is not a routine clinical practice due to the invasiveness of the endoscopy procedure, time consuming nature, the availability of laboratory culture facilities, and cost considerations\[[@B17]\]; non-invasive methods are being developed\[[@B18]\].

PROSPECTS OF NEW STRATEGIES FOR ENSURING ERADICATION OF *H. PYLORI* AND PREVENTION OF ANTIMICROBIAL RESISTANCE
==============================================================================================================

A new strategy that could provide sufficient eradication rates as well as decrease the amount of antibiotics is essential for the prevention of future antimicrobial resistance of *H. pylori*. Dual therapy with AMPC and PPI could be a possible solution because this regimen is a single-antibiotic therapy, and it is well known that *H. pylori* is hardly resistant to AMPC. Currently, the resistance rates of *H. pylori* to AMPC remain low (0%-5%)\[[@B19],[@B20]\]. A dual therapy comprising a PPI and AMPC was first introduced in the 1990s as a first-line regimen for *H. pylori* infection\[[@B21]\]. As dual therapy of PPI and AMPC administered at standard doses did not achieve satisfactory treatment outcomes\[[@B22],[@B23]\], it was subsequently used as a salvage treatment. Recently, Yang et al\[[@B24]\] reported that a high-dose dual therapy consisting of AMPC and rabeprazole achieved an eradication rate of 95.3% in first-line therapy, and 89.3% in rescue therapy. However, this method needed a high frequency and a high dose of AMPC and PPI for a longer duration (*e.g*., rabeprazole 20 mg and amoxicillin 750 mg 4 times/d for 14 d) to attain an acceptable eradication rate of \> 90%, which led to high cost, adverse side effects, and poor patient compliance.

One interesting possibility is to substitute conventional PPIs with vonoprazan for use in dual therapies. Vonoprazan-based dual therapy could be an alternative treatment regimen for *H. pylori* eradication, which could provide sufficient eradication rates of *H. pylori* and minimize antimicrobial resistance. The key to a successful dual therapy regimen is a PPI-generated neutral environment suitable for bacterial growth; this causes dormant *H. pylori* to enter a replicative state and makes *H. pylori* sensitive to AMPC. Vonoprazan is a novel potassium competitive acid blocker that has a strong and long-lasting effect on inhibition of acid secretion\[[@B25],[@B26]\]. In addition, the pharmacokinetic features of vonoprazan are not affected by CYP2C19 polymorphisms\[[@B27],[@B28]\]. It is reported that seven days of standard triple therapy containing vonoprazan provided approximately 90% eradication rate attributable to effective gastric acid inhibition and the maintenance of a high gastric pH, and had a high safety profile irrespective of age\[[@B29]-[@B31]\]. To the best of our knowledge, there is only one study on vonoprazan and AMPC dual therapy; this study showed that a regimen consisting of vonoprazan 20 mg twice per day and AMPC 500 mg three times/d for seven days provided sufficient eradication rates of 93.8% of *H. pylori* infection\[[@B32]\]. This seven-day, vonoprazan-based dual therapy may have additional advantages in terms of treatment compliance and medical costs as fewer agents are used and the duration of the therapy is shorter than that of other recent standard treatment regimens (such as BQT, CQT, and sequential therapies). Vonoprazan-based dual therapy may be a recent breakthrough that could ensure a satisfactory eradication rate with the use of minimum antibiotic agents and a short treatment duration. Furthermore, reducing antibiotics may prevent changes and dysbiosis in gut microbiota composition, which are caused by antibiotics used in *H. pylori* eradication therapy\[[@B33]\]. Although vonoprazan-based dual therapy potentially has these advantages, it also has several limitations for implementation in clinical setting. First, vonoprazan is available in a few countries. Vonoprazan was developed and launched in Japan in 2015. However, it is now available in several Asian countries including Philippine, Singapore, and Thailand, and has been approved in other regions, including South America (countries such as Argentina and Peru). Thus, vonoprazan may become available and can be used for *H. pylori* eradication therapy worldwide in the near future. Second, this regimen cannot be used in patients with penicillin allergy and thus antimicrobial susceptibility testing should be performed in these patients to optimize *H. pylori* eradication therapy. Although the conventional antimicrobial susceptibility testing is invasive due to the need of endoscopy and biopsy as mentioned above, a non-invasive molecular test using fecal sample has also been recently developed\[[@B34]\]. This method involves the isolation of *H. pylori* DNA from stool and detection of point mutations conferring antimicrobial resistance by polymerase chain reaction. This method should be considered for testing antimicrobial susceptibility in patients with penicillin allergy before *H. pylori* eradication therapy. Finally, there are few data and studies regarding this regimen. Further studies should be conducted to prove its efficacy and safety profile.

CONCLUSION
==========

In this review, we outline the urgent, global issue of *H. pylori* antimicrobial resistance and propose our prospects of approach for the issue. *H. pylori* treatment is becoming more challenging because of the increasing antimicrobial resistance to not only CAM but also to MNZ and fluoroquinolones. Thus, there is a need to develop new *H. pylori* eradication therapies that provide an acceptable eradication rate, better safety and tolerability profile, and good patient compliance, while preventing the increase in *H. pylori* antimicrobial resistance. One interesting possibility is the use of vonoprazan in dual therapy with AMPC, which has been shown to have over a 90% eradication rate. Large scale, randomized control trials should be conducted to verify and establish this finding in the future.
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